trial

Novel Smoking Cessation Drug for Schizophrenia

NCTId NCT02230384
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 62 (actual)
Sponsored by K.N. Roy Chengappa
Primary completion 2016-12-16
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
62 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2014-09
Primary completion
2016-12-16
Eligibility
ALL · 18 Years · 66 Years

Interventions & indications

Drugs
Active JNJ Drug

Sponsors

K.N. Roy ChengappaLead Sponsor
University of Pittsburgh Medical CenterCollaborator
National Institutes of Health (NIH)Collaborator
Virginia Commonwealth UniversityCollaborator

Investigators

1
K.N. Roy Chengappa, MDPrincipal Investigator

Sites

1 total
Pittsburgh, United States

Linked catalysts

1
Novel Smoking Cessation Drug for Schizophrenia — primary completion2016-12-16

Facts & assertions

4 sourced
Enrollment
62
Phase
PHASE2
Primary Completion Date
2016-12-16
Status
COMPLETED
relationships
The graph out of here
drug
Active JNJ Drug
drug
lead_sponsor
K.N. Roy Chengappa
company
collaborator
University of Pittsburgh Medical Center
company
National Institutes of Health (NIH)
company
indication
Smoking Cessation
indication
Schizophrenia
indication
Smoking Cessation
indication
investigator
K.N. Roy Chengappa, MD
person